Regeneron Pharmaceuticals (REGN.O) surged 4% Wednesday after the FDA approved Pasatru for a bone-hardening disorder, adding a second approved rival to Ipsen’s Sohonos in a market affecting fewer than 1,000 diagnosed patients globally.1
The approval hands Regeneron a commercial foothold in an ultra-orphan segment where pricing power is typically high, and it arrives as biotech investors are scrutinising rare-disease pipelines for M&A and licensing potential.
Key Takeaways
- FDA clears garetosmab (Pasatru) for adults with fibrodysplasia ossificans progressiva.
- Trial data showed up to 94% reduction in new abnormal bone formation.
- Ipsen, Incyte, Mirum Pharma and Ashibio all compete in the same space.
Market Reaction & Competitive Context
REGN.O’s 4% gain on Wednesday outpaced the broader XBI biotech index, which was roughly flat on the session, underscoring how meaningful a rare-disease approval can be for a large-cap name looking for pipeline diversification beyond its flagship Dupixent franchise.1
Pasatru now competes directly with Ipsen’s Sohonos, an oral retinoid approved in 2023 and currently the only other U.S.-cleared therapy for fibrodysplasia ossificans progressiva (FOP). Incyte (INCY.O) and partner Mirum Pharmaceuticals (MIRM.O), along with privately held Ashibio, are also advancing candidates, signalling that the rare-disease niche is drawing concentrated industry attention despite its small addressable patient base.1
Detailed Analysis: Mechanism and Trial Data
Pasatru is an injectable antibody that blocks Activin A, a protein that triggers the aberrant bone-growth cascade in FOP patients – a mechanism distinct from Sohonos, which works via the retinoic acid pathway.1 That differentiation could allow both drugs to coexist or prompt clinicians to sequence therapies, depending on tolerability profiles.
In a 56-week, 63-patient pivotal trial, the 3 mg per kg dose of Pasatru reduced new heterotopic bone lesions by 94% versus placebo, while the 10 mg per kg dose produced a 90% reduction – both statistically compelling results for a disease where no prior therapy had demonstrated such efficacy in a late-stage study.1
FOP is caused by a gain-of-function mutation in the ACVR1 gene and affects roughly one in two million people worldwide, with approximately 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.1 The tiny patient population typically supports premium orphan-drug pricing, a dynamic that makes even modest commercial penetration financially significant.
The path to approval was not straightforward. In 2020, Regeneron paused dosing in a mid-stage trial after five patient deaths, ultimately discontinuing that study and collaborating with global regulators to redesign the late-stage programme that underpinned Wednesday’s clearance.1 That history of regulatory engagement may inform how physicians and payers assess the drug’s long-term safety profile.
Outlook & Management Commentary
Regeneron’s clinical team member Susan Rhee said the company is planning to initiate a paediatric trial later this year, a move that could broaden the label and extend market exclusivity through paediatric priority review voucher incentives.1
“The company is planning to start a trial for children later this year,” Rhee told Reuters, pointing to the next clinical milestone investors should monitor.
A paediatric expansion would be strategically important: FOP manifests in childhood, meaning adult-only labelling captures only a fraction of the potential treatment window and leaves Regeneron exposed to off-label competition from Sohonos, which already has broader usage patterns in clinical practice.
Conclusion
Wednesday’s approval adds a rare-disease revenue stream to Regeneron’s portfolio at a time when the sector is under pressure to demonstrate pipeline depth beyond dominant single assets. With at least four companies now active in FOP drug development – and M&A appetite for orphan-disease franchises running high – Pasatru’s commercial trajectory will be closely watched as a read on competitive positioning and potential licensing interest in the space.
Not investment advice. For informational purposes only.
References
1Banerjee, Bageshri and Santhosh, Christy (2026-08-19). “US FDA approves Regeneron’s rare bone disorder drug”. Reuters. Retrieved 2026-08-19.